Kinaxis, a leading provider of enterprise supply chain orchestration solutions, has announced that Swedish Orphan Biovitrum AB, commonly known as Sobi, will implement the Kinaxis Maestro platform. This decision will enable Sobi to enhance collaboration within its partner network, make decisions based on data, and ensure that essential therapies reach patients who rely on them.
Health Technology Insights: Low Access To COVID Pills Despite High Awareness: Global Healthy Living Foundation Report
Sobi is a biopharmaceutical company based in Stockholm, specializing in hematology, immunology, and specialty care. It operates in 55 countries and provides treatments to over 40,000 patients each year. Given that many rare diseases are not well addressed by existing healthcare solutions, Sobi faces a high level of urgency and complexity within its supply chain. This requires the company to maintain speed, precision, and visibility throughout all stages of its operations.
The Maestro platform provides tools such as scenario planning, centralized data management, and attribute-based planning. These features will help Sobi improve its relationships with partners, scale its operations, and quickly respond to any disruptions. This, in turn, supports the continuous supply of life-critical therapies for patients suffering from rare conditions.
Health Technology Insights: Applied Policy Welcomes Cheryl Powell as Vice President of Health Policy
Norbert Schoellhorn, vice president of global manufacturing and supply chain at Sobi, stated that Kinaxis is well known in the life sciences sector for its deep understanding of the unique challenges this industry faces. He noted that the team at Kinaxis believes that Maestro will enhance responsiveness, strengthen connectivity with partners, and ultimately help deliver treatments more quickly to patients who cannot afford to wait.
Fabienne Cetre, executive vice president of EMEA at Kinaxis, expressed pride in supporting Sobi’s mission and believes the Maestro platform will enable real-time collaboration and smooth execution, accelerating the delivery of essential therapies worldwide. Kinaxis is already trusted by many prominent companies in the life sciences industry, including Merck, Novartis, Bristol Myers Squibb, Cardinal Health, Boston Scientific, and Servier. Deloitte Nordics has been tasked with leading the implementation of Maestro for Sobi, ensuring that the rollout meets the high standards required for this important initiative.
Health Technology Insights: Health Technology Insights: Latest News And Innovations – Roundup 26 September 2025
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
